New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
08:18 EDTROSGRosetta Genomics provides product pipeline update
Rosetta Genomics announces details regarding the company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics. Kenneth A. Berlin, president and CEO of Rosetta Genomics stated, "Rosetta Genomics continues to set the pace in developing and commercializing microRNA-based technologies. We have the most validated microRNA biomarker platform with approximately 50 peer-reviewed publications relating to our platform and have recently rejuvenated our research and development efforts to leverage this leading and versatile platform. We are moving forward on a variety of important projects to provide clinicians with better tools to improve patients' lives in a number of areas of unmet medical need with an aim to commercialize one new assay per year commencing in 2015. Building upon the company's four current commercial diagnostic assays, Rosetta is advancing several new diagnostic assays starting with our lead assay for the differential diagnosis of thyroid neoplasia. In addition, we are evaluating several assays for other cancers as well as assays for non-invasive diagnosis of chronic kidney rejection; the early diagnosis and risk stratification of heart failure patients; and the early diagnosis and differentiation of Alzheimer's disease."
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
08:32 EDTROSGRosetta Genomics launches BRAF mutation assay
Rosetta Genomics announced the launch of a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. This newest assay will complement its broad offerings so that oncologists can optimize treatment decisions for their cancer patients. Rosetta Genomics' BRAF mutation analysis test utilizes highly specific and sensitive Competitive Allele-Specific TaqMan PCR technology that can detect as little as 0.5% mutated DNA in a large, normal DNA sample. BRAF mutations occur in up to 50% of malignant melanomas, and several FDA-approved BRAF inhibitor therapies have been introduced to the market for use in patients with late-stage metastatic melanoma.
October 8, 2015
07:24 EDTROSGAegis to hold a conference
Subscribe for More Information
September 30, 2015
09:18 EDTROSGRosetta Genomics announces partnership with FNApath
Rosetta Genomics announces that the company has reached an agreement-in-principle with FNApath of Little Rock, Arkansas, under which Rosetta Genomics will provide endocrinologists initially testing their patients for thyroid cancer with the option of using a pathologist or laboratory of their own choosing, or FNApath, a centralized laboratory with an expertise in diagnosing thyroid cancer. In the event of an indeterminate result, the sample would then be tested with RosettaGx Thyroid Reveal, the company's thyroid neoplasia assay for the differential diagnosis of indeterminate fine needle aspirates, or FNAs.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use